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The role of postoperative chemotherapy in patients who  
undergoing surgery following chemoradiotherapy of initially 
unresectable rectal cancer
Michał Jankowski1, 2, Manuela Las-Jankowska1, 3,  
Dariusz Bała1, 2, Wojciech Zegarski1, 2
Introduction. Preoperative chemoradiotherapy (preCRT) improves local control of rectal cancer and such is parti-
cularly merited for treating locoregionally advanced tumors. Nevertheless, the role of postoperative chemotherapy 
(postCT) in such patients is currently disputed. 
Materials. Subjects were 75 patients with unresectable cT3–4 and/or N+ tumors who underwent radical surgery 
following preCRT between January 2003 and December 2012 at the Oncology Centre in Bydgoszcz. PostCT was 
subsequently used in 32 (43%) of these patients. 
Results. There were 20 abdominoperineal resections (APR), 50 anterior resections (AR) and 5 Hartmann’s procedures 
(HART) performed in the patient group, where respectively 30%, 46% and 60%, received systemic treatment. Based on 
postoperative histopathological assessment, disease staging was assigned as follows: stage III for 32 (43%), patient-
s,stage II for 22 (29%) and stage I for 15 (20%). Pathologic complete pathological response (pCR) was seen in 6 cases 
(8%). In the postCT+ group, disease stage III was observed in 13 (41%) patients. A three-year survival was observed 
in 43 patients; 25 (58%) and 18 (56%) of patients respectively undergoing either postCT– or postCT+. A five-year 
survival was noted in 26 patients; 19 (44%) and 7 (22%) in both groups, respectively. 
Conclusion. Together with the most recent reports, our study demonstrates that postoperative chemotherapy has 
no significant effect on the outcomes of oncological treatment in those patients having undergone preoperative 
chemoradiotherapy for locoregionally advanced rectal cancer. 
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Introduction 
Rectal cancer (ICD 10: c20) is the most common location 
of colorectal cancer, of which in 2013, there were 5898 pe-
ople diagnosed with this condition in Poland [1]. Therapy is 
determined by the disease stage upon diagnosis and invo-
lves a number of surgical procedures, as well as radio- and 
chemotherapies. In locoregionally advanced tumors, the 
most common treatment involves a surgical resection and 
radiation therapy combined with systemic treatment. It is 
therefore crucial that preoperative diagnostics and eligibility 
for treatment (MRI, CT) be appropriately applied to patient 
diagnosis and treatment. 
Methods 
“Unresectable rectal cancer”
This should be diagnosed before surgery, when perfor-
ming radical resection is fraught with uncertainty due to the 
risk of positive surgical margins. The tumor is most common-
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ly immobile during rectal examination (Tab. I). Pelvic MRI 
scans are the most efficacious means for diagnosing rectal 
tumors. An “unresectable rectal cancer” without distant me-
tastases occurs in about 10% of patients with rectal cancer. 
Preoperative treatment 
Perioperative radiotherapy reduces the local recurrence 
rate in patients with rectal cancer [2, 3]. When used prior 
to the main treatment, it also allows the desired outcome 
to be achieved with a lower toxicity [4]. Reduced tumor 
size is usually observed several weeks after radiotherapy 
is completed [5, 6]. Combining chemo- and radiotherapy 
increases treatment efficacy [7]. 
The treatment regimen for the study group consisted 
of 28 fractions of 1.8–2 Gy per fraction and a 5.4 Gy bolus. 
Postoperative chemotherapy 
This has been used since the 1970s, after studies had 
been published on its efficacy in dealing with colonic cancer 
patients; being based on fluoropyrimidine [8]. Such therapy 
showed that the overall survival (OS) and disease-free sur-
vival (DFS) rates could be improved by more than 10% [9]. 
Rectal cancer patients are qualify for this treatment be-
cause the indications are similar to those of colon cancer. The 
standard duration lasts about 24 weeks, with the treatment 
being well tolerated, with the most important of the side ef-
fects being cardiotoxicity affecting its therapeutic tolerance. 
In recent years using postoperative chemotherapy in 
patients with rectal cancer, particularly following earlier 
preoperative chemoradiotherapy, is widely considered con-
troversial and is disputed. 
Prognosis 
Prognoses for rectal cancer patients, i.e. overall survival, 
(OS), disease free survival (DFS), depends on how radical 
resection (R0) is performed with total mesorectal excision 
(TME) [10]. Locoregionally advanced rectal cancer (cT3–4 
and/or cN0/+) is associated with higher local recurrence 
rates following surgical curative treatment during the posto-
perative period. Preoperative chemoradiotherapy (preCRT) 
facilitates local control over rectal cancer; increasing the 
numbers of R0 resections and decreasing local recurrence 
rates. This type of treatment is especially justified for loco-
regionally advanced tumors. 
Despite the progress achieved in local and regional 
treatment, the final outcomes in rectal cancer are still go-
verned by the ≈ 25% rate of distant metastases following 
radical resection.
Material
Subjects were 787 patients with WHO stage I–III rectal 
tumors that underwent radical surgery between 2003–2012 
at the Department of Oncological Surgery of the Nicolaus 
Copernicus University Medical Centre, Centre of Oncology 
in Bydgoszcz. Seventy-five patients were preoperatively 
diagnosed (by computed tomography/magnetic resonance 
of the pelvis and abdomen) with cT3–4 and/or cN0/+ stage 
and qualified for preoperative chemoradiotherapy (28 frac-
tions: 25/1.8 Gy, and bolus 5.4 Gy, combined with 2 cycles 
of 5Fu with leucovorin). 
After surgery, postoperative chemotherapy (post-CT+) 
was administered to 32 patients while 43 did not undergo 
any postoperative systematic treatment (post-CT–). In the 
former group, 13 patients did not receive the complete 
treatment (8 cycles 5Fu/Leu, 40%). Table II presents the 
characteristics of these two study groups. 
The reasons for abandoning the systemic treatment 
(post-CT–) are listed in Table III.
Results 
There were no statistically significant differences found 
when comparing 5-year overall survival (OS) rates between 
both groups as estimated by the Kaplan-Meier method 
(Fig. 1). Nor were any such differences observed in either 
of the 5-year disease-free survival (DFS) rates. 
Table I. “Unresectable” rectal cancer
At least one of the following criteria:
Immobile upon per rectum examination
Adhesion or infiltrating adjacent organs (cT4)
Neoplastic infiltration of mesorectal fascia sized 1 mm or smaller
Table II. Patients’ characteristics (n = 75)
post-CT+ post-CT– Total
Above 75 years of age 4 6
Below 75 years of age 28 37
AR 50
APR 20
HR 5
I/II 19 24 33
III 13 19 32
Table III. Causes for abandoning adjuvant chemotherapy (post-CT–)
Cause (n = 43)
Inadequate qualifications of the oncologist — age 5
Inadequate qualifications of the oncologist — other 12
Extension of postoperative period — complications 6
Extension of postoperative period — other 4
Other 4
Unknown 12
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The overall (n = 75) rate of local recurrences was 14%, 
without any statistically significant difference between 
groups (Tab. IV). The local recurrence rate was higher in 
groups at the lower tumor stages by 4.2% [11]. 
Discussion 
The effect of postoperative chemotherapy 
on overall survival (OS) and disease-free 
survival (DFS) in patients after preoperative 
chemoradiotherapy
Indications for postoperative chemotherapy in patients 
undergoing radical treatment of rectal cancer are largely 
based on the outcomes of colonic cancer treatment which 
show a 24–33% reduced risk of death as a result of post-CT 
in patients with regional metastases (pN+) [12].In their ana-
lysis mainly based on studies prior to 2000 and without the 
use of the TME technique, Petersen et al. reported relative 
improvements in OS and DFS following post-CR, respectively 
amounting to 17% and 25% [13]. 
Nevertheless adjuvant chemotherapy in rectal cancer 
patients after previous preoperative therapy has been the 
subject of a significant dispute/controversy in recent years. 
In their meta-analysis based on 4 studies [14–17] and the 
data from 1196 patients, Breugom et al. [18] demonstrated 
that postoperative chemotherapy had no effect on impro-
ving overall survival (OS), nor disease-free survival (DFS) or 
on the rates of all recurrences. 
Similar results were published by Bujko et al. in their 
meta-analysis based on similar study material [19]. 
Nonewithstanding In addition, Bujko et al. observed a be-
neficial effect of postoperative chemotherapy on DFS (2.5% 
difference in 5-year DFS rates; HR = 0.92, 95% CI: 0.80–1.04, 
p = 0.047), with no effect on 5-year OS rates (p = 0.39) in trials 
conducted on patients randomized after surgical treatment 
(PROCTOR/SCRIPT; CHRONICLE; QUASAR) [16, 17, 20]. For stu-
dies on patients randomized before preoperative radiotherapy 
(EORTOC, ITALIAN) [14, 15], no effect of postoperative chemo-
therapy could be observed regarding either DFS or OS rates.
The importance of the distance between the tumor 
and the anorectal line 
When tumors are located within the upper part of rec-
tum (10–15 cm), postoperative chemotherapy beneficially 
affects disease free survival and the incidence of distant 
metastases [14]. However, one should keep in mind that for 
tumors located within the upper part of the rectum (more 
than 10 cm from the anorectal line), preoperative radiation 
should be administered only in exceptional cases [21]. 
An analysis by the Swedish Cancer Registry based on 
436 patients aged above 75 years suffering regional disease 
(WHO stage III), confirms that postoperative chemotherapy 
is effective only in tumors located more than 10 cm above 
the anorectal line (HR 0.54; 95% CI 0.3–0.9, p < 0.05) [22]. 
Such results may be explained by the similarities in anato-
mical structure of the colon and the upper rectum.
Table IV. Treatment outcomes
post-CT+ post-CT– Total
n 32 43 75
Local recurrence
5 6 11
15.6% 13.9% 14.7%
Figure 1. Overall survival (OS) in patients from both groups (with and without postoperative chemotherapy)
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Locoregional advanced
In locoregionally advanced (cT3–4, mrf+) and/or regio-
nally advanced (cN+), the most effective treatment invo-
lves preoperative radiotherapy, if possible combined with 
chemotherapy and a radical (R0) resection procedure by 
means of the total mesorectal excision (TME) technique [21]. 
Despite such management, the rates of recurring disease 
are significantly higher in this group [23]. Correct preope-
rative diagnostics, preferably by means of pelvic magnetic 
resonance imaging [24] is thus the crucial element of patient 
diagnosis that facilitates customization of treatment. 
In the retrospectively analyzed group, postoperative 
chemotherapy was found not to improve oncological out-
comes (OS, DFS) despite that the comparison was conducted 
between apatient group treated according to optimum 
principles (post-CT+) and a heterogeneous patient group 
in whom systemic treatment was abandoned (post-CT–). 
A randomized trial is thereby needed to confirm that sys-
temic treatment has no effect overall outcomes. 
Conclusions
Despite abandoning postoperative chemotherapy, OS 
and DFS rates were not reduced in patients undergoing 
radical surgical treatment following preoperative chemo-
radiotherapy of locoregional advanced rectal cancer.
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